Siltuximab

Drug Profile

Siltuximab

Alternative Names: Anti-interleukin-6 monoclonal antibody - Centocor; cCLB8; Chimeric anti-interleukin-6 monoclonal antibody - Centocor; CNTO-328; Sylvant

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Centocor
  • Developer Centocor; Janssen Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant lymph node hyperplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant lymph node hyperplasia
  • Phase II Multiple myeloma
  • Phase I Paraproteinaemia
  • Discontinued Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 18 Jun 2015 Siltuximab is still in phase II trials for smoldering Multiple myeloma (First-line therapy, Monotherapy) in USA, Australia, Belgium, France, Germany, Greece, Israel, South Korea, Spain, Sweden and the United Kingdom
  • 14 May 2015 Siltuximab is still in phase II trials for Giant lymph node hyperplasia in Australia, Brazil, China, Egypt, Hong Kong, India, Israel, Malaysia, New Zealand, Russia, Singapore, South Korea and Taiwan
  • 04 Dec 2014 Registered for Giant lymph node hyperplasia in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top